Disappearing Polymorphs: The Ritonavir Crisis and the Hidden Chemistry of Drug Crystals

Overview

Veritasium tells the cautionary tale of ritonavir, a once life-saving HIV drug, that began to fail its dissolution tests after two years of flawless production. The narrative follows a global investigation into a disappearing polymorph and how tiny seed crystals could spread a more stable, insoluble form across facilities worldwide.

Key insights

• How polymorphism can dramatically alter a drug’s effectiveness by changing solubility and dissolution.
• The birth of a seed-crystal hypothesis and the idea that contamination can propagate across production sites.
• The historical parallel with the Wohler–Liebig debate and the realization that bond arrangement matters as much as composition.
• The implications for industry practice, regulation, and the precautionary shift toward safer formulations.

Introduction

This video examines ritonavir, a drug that transformed a terminal diagnosis into a manageable condition for HIV patients. by mid-1990s ritonavir was widely used, but a dormant risk emerged when a previously stable semi-solid formulation began producing capsules that failed the dissolution test. This set off a cascading investigation into what could be happening inside the crystals, how a seemingly identical molecule could behave differently, and what this meant for patients relying on the medicine.

The Ritonavir Crisis

The dissolution test is a rigorous standard in pharmaceutical manufacturing, ensuring that a drug releases its active ingredient at a predictable rate for proper absorption. For ritonavir, 240 consecutive lots had never failed, but suddenly a batch wasn’t dissolving properly. The line was shut down, batches destroyed, lines deep cleaned, and QA initiated a global search for the root cause. The investigation expands beyond Chicago to Italy and beyond, highlighting how a problem in one place can threaten patients worldwide.

“They were both right. Yeah, like, they both had a compound that was made of exactly one carbon, one nitrogen, one oxygen, and one silver atom.” - Veritasium

Crystallography and the Disappearing Polymorph

Analysts at the lab find the white capsules initially appear to be ritonavir, but under the microscope, they reveal millions of tiny needles—crystals that are a new polymorph. The chemistry team tests ritonavir synthesized in the lab and confirms the same crystal needles. The problem is that this new form is extraordinarily stable and less soluble, which means poor or no dissolution, effectively nullifying the drug’s action.

Abbott halts production, but patients need the medicine. The company mobilizes resources, rebuilds facilities, and considers alternative sites as the search for a fix continues.

The Bonding Story: From Wohler and Liebig to Abbott

The video then moves to a historical detour: Justus von Liebig and Friedrich Wohler’s 19th-century debate about a compound that looked the same but behaved differently when burned. The experiments demonstrate that the arrangement of bonds—how atoms are connected—matters as much as the elemental composition. This is the birth of the concept of isomers and, more importantly, polymorphs in solids. Ritonavir’s Form II resembles Form I in molecular composition, but the crystal structure makes Form II far more stable and less soluble.

“They had discovered isomers that it's not just the atoms in a molecule that dictate how it behaves, but its bonds as well.” - Veritasium

Polymorphs, Spectra, and Crystal-Form Energy Landscapes

In chemistry, infrared spectroscopy can fingerprint a molecule by showing peaks corresponding to bond vibrations. ritonavir’s Form II has a spectrum that mirrors ritonavir’s bonds, but subtle shifts reveal that the bonds’ arrangement has changed. The video uses a chocolate demonstration to illustrate polymorphism: chocolate has six polymorphs with different melting points. The art of tempering chocolate—managing temperature and time—mirrors how pharmaceutical processes must carefully navigate crystal forms to achieve a desirable Form V, which is stable and has the right melting characteristics, while avoiding Form II’s stability that makes it dissolve slowly or not at all.

“This is what the scientists at Abbott suspected might be happening to ritonavir. They knew that the spectrum of ritonavir should look like this, but instead they saw the same peaks with slight deviations.” - Veritasium

Seed Crystals, Tin Pest, and the Global Spread

The core narrative turns into a propagation story. Seed crystals, tiny impurities or dust particles acting as nucleation sites, lower the barrier to crystallization and can seed Form II across production lines. The film draws a vivid parallel to tin pest, where gray tin forms and spreads like an infection, tearing apart metal objects. In ritonavir, seed crystals could travel via clothing, air currents, or cross-contamination between facilities, turning Form I into Form II across multiple sites. The grim implication is that even with perfect process control, random seeds can irreversibly transform a drug’s solid form, challenging manufacturers to prevent such transitions entirely.

“Once a tiny bit of form two appeared, it acted as a nucleation site, lowering that massive activation energy and causing all the Form I to crystallize into form II.”

Abbott’s Response and Industry Implications

Abbott’s response spans months of research, facility changes, and site testing. They explore alternative production sites (Italy) that could produce ritonavir without Form II contamination, while Chicago reassesses its own process. The team concludes that Form II’s barrier is extremely tall, making conversion back to Form I near-impossible, and that once seeds spread, stopping the spread becomes a near-impossible task. The broader consequence is a reinforcement of regulatory scrutiny around polymorph screening, ensuring that manufacturers account for multiple solid forms, potential seed catalysts, and the risk of disappearing polymorphs. The video closes with reflections on how the industry now screens for polymorphs, the costs of prevention, and the importance of contingency formulations as a safety net.

Lessons and Outlook

The ritonavir crisis catalyzed a shift in how pharmaceutical companies approach crystallography, process control, and patient safety. It underlines the unpredictable nature of polymorphism and the need for cross-site QA, robust seed-crystal testing, and diversified formulations. Abbott’s decision to revert to an older liquid formulation shows how a safety net can protect patients when a solid-state risk becomes unmanageable. The video emphasizes that while such events are rare, they have outsized consequences, prompting ongoing regulatory and research investments in polymorph screening, crystallography, and manufacturing resilience.

Conclusion

The ritonavir case is a striking illustration of how the microscopic arrangement of atoms and their bonds can determine macroscopic outcomes such as drug dissolution and patient outcomes. It is both a cautionary tale and a blueprint for how science, industry, and regulation can collaborate to mitigate rare but potentially catastrophic risks in the pharmaceutical supply chain.

“A transformation that we believed was a scientific and chemical impossibility.” - Veritasium